Regeneron Pharmaceuticals Inc (REGN)
958.64
+1.64
(+0.17%)
USD |
NASDAQ |
May 06, 16:00
946.64
-12.00
(-1.25%)
Pre-Market: 08:07
Regeneron Pharmaceuticals Free Cash Flow (Quarterly): 1.351B for March 31, 2024
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 1.351B |
| December 31, 2023 | 776.20M |
| September 30, 2023 | 914.40M |
| June 30, 2023 | 888.50M |
| March 31, 2023 | 1.088B |
| December 31, 2022 | 1.468B |
| September 30, 2022 | -440.40M |
| June 30, 2022 | 410.80M |
| March 31, 2022 | 1.960B |
| December 31, 2021 | 2.218B |
| September 30, 2021 | 3.280B |
| June 30, 2021 | 478.20M |
| March 31, 2021 | 553.20M |
| December 31, 2020 | 1.070B |
| September 30, 2020 | -407.50M |
| June 30, 2020 | 813.50M |
| March 31, 2020 | 527.90M |
| December 31, 2019 | 648.40M |
| September 30, 2019 | 435.60M |
| June 30, 2019 | 93.70M |
| March 31, 2019 | 822.70M |
| December 31, 2018 | 643.30M |
| September 30, 2018 | 346.70M |
| June 30, 2018 | 282.60M |
| March 31, 2018 | 539.40M |
| Date | Value |
|---|---|
| December 31, 2017 | 459.30M |
| September 30, 2017 | 355.18M |
| June 30, 2017 | -85.42M |
| March 31, 2017 | 305.44M |
| December 31, 2016 | 239.97M |
| September 30, 2016 | 532.47M |
| June 30, 2016 | 260.66M |
| March 31, 2016 | -59.10M |
| December 31, 2015 | 104.04M |
| September 30, 2015 | 746.75M |
| June 30, 2015 | 17.94M |
| March 31, 2015 | -215.89M |
| December 31, 2014 | 80.63M |
| September 30, 2014 | 84.55M |
| June 30, 2014 | 265.54M |
| March 31, 2014 | -11.30M |
| December 31, 2013 | 212.75M |
| September 30, 2013 | 60.76M |
| June 30, 2013 | 93.71M |
| March 31, 2013 | 65.04M |
| December 31, 2012 | 78.02M |
| September 30, 2012 | -12.63M |
| June 30, 2012 | -91.25M |
| March 31, 2012 | -98.10M |
| December 31, 2011 | -61.61M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-440.40M
Minimum
Sep 2022
3.280B
Maximum
Sep 2021
906.34M
Average
794.85M
Median
Free Cash Flow (Quarterly) Benchmarks
| Vertex Pharmaceuticals Inc | 118.50M |
| Amgen Inc | 459.00M |
| Eli Lilly and Co | 83.20M |
| Moderna Inc | -1.185B |
| Gilead Sciences Inc | 2.219B |